Patents by Inventor Christopher Scott Neumann

Christopher Scott Neumann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
    Patent number: 11931414
    Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is conjugated to a targeting Ligand Unit through quaternization by a Linker Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as those of cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: March 19, 2024
    Assignee: Seagen Inc.
    Inventors: Christopher Scott Neumann, Kathleen Olivas, Robert Lyon, Kung-Pern Wang
  • TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS
    Publication number: 20240016953
    Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is linked to a targeting Ligand Unit through a Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.
    Type: Application
    Filed: March 3, 2023
    Publication date: January 18, 2024
    Inventors: Christopher Scott Neumann, Kathleen Olivas
  • CHARGE VARIANT LINKERS
    Publication number: 20230173093
    Abstract: The present disclosure provides, inter alia, ADCs with charge variant chemical linkers useful in treating various diseases such as cancer and autoimmune disorders.
    Type: Application
    Filed: April 9, 2021
    Publication date: June 8, 2023
    Inventors: Christopher Scott NEUMANN, Joshua HUNTER
  • Targeted delivery of nicotinamide adenine dinucleotide salvage pathway inhibitors
    Patent number: 11638762
    Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is linked to a targeting Ligand Unit through a Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: May 2, 2023
    Assignee: Seagen Inc.
    Inventors: Christopher Scott Neumann, Kathleen Olivas
  • QUATERNIZED NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITOR CONJUGATES
    Publication number: 20200197524
    Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is conjugated to a targeting Ligand Unit through quaternization by a Linker Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as those of cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.
    Type: Application
    Filed: April 27, 2018
    Publication date: June 25, 2020
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Christopher Scott Neumann, Kathleen Olivas, Robert Lyon, Kung-Pern Wang
  • TARGETED DELIVERY OF NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS
    Publication number: 20190314519
    Abstract: Compounds and compositions are disclosed in which a NAMPT Drug Unit is linked to a targeting Ligand Unit through a Unit from which a NAMPT inhibitor compound or derivative thereof is released at the targeted site of action. Methods for treating diseases characterized by the targeted abnormal cells, such as cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.
    Type: Application
    Filed: October 18, 2017
    Publication date: October 17, 2019
    Applicant: SEATTLE GENETICS, INC.
    Inventors: Christopher Scott Neumann, Kathleen Olivas